Sutter Health adopting more AI to prevent medical errors
Sutter Health is deploying a new technology to better detect early-stage lung cancers and cut down on preventable medical errors that can cause death. The technology includes an artificial intelligence platform developed by Ferrum Health Inc., a San Francisco-based startup that was founded in 2017. Sutter will extend its partnership with Ferrum to its medical imaging departments across its entire system, said Dr. Jason Wiesner, a radiologist and the medical director of Sutter’s diagnostic imaging…
This study delves into the mechanisms by which a short period of fasting can accelerate wound healing. Fasting triggers many of the same cellular stress responses, such as upregulated autophagy, as occur during the practice of calorie restriction. It isn't exactly the same, however, so it is always worth asking whether any specific biochemistry observed in either case does in fact occur in both situations. In particular, the period of refeeding following fasting appears to have beneficial effects that are distinct from those that occur while food is restricted. Multiple forms of therapeutic fasting have been repor...
Carbohydrate antigen 125 (CA125), a marker for ovarian cancer, is thought to be associated with the clinical severity of heart failure (HF) and fluid congestion. Mesothelial cells in the pericardium, pleura, peritoneum and M ¨ullerian epithelium produce CA125 presumably in response to mechanical (congestion) stress. With the growing use of left ventricular assist device (LVAD) for advanced HF, assessment of right ventricular (RV) function and hemodynamics is of major interest. We aimed to assess CA125 as a predictor of right heart function and hemodynamics.
African Americans (AA) have worse survival compared to Caucasians after heart transplantation (HTx). We assessed whether AA are at higher risk of acute cellular rejection (ACR), graft failure (GF) and cancer when compared to Caucasians and Other races in the modern era.
Gene expression profile (GEP) monitoring by AlloMap ® is ISHLT-guideline recommended for graft surveillance after heart transplant (HT). The Outcomes in AlloMap Registry (OAR) is an observational, prospective study of HT patients monitored by AlloMap. The effect of malignancy on AlloMap scores is not well characterized. The large cohort of OAR patie nts with clinical data associated with AlloMap scores permits this characterization.
Polyfunctional T cells (PTC) have the ability to secrete ≥2 cytokines per cell when stimulated and increased presence of PTC is associated with favorable outcomes in patients undergoing chimeric antigen receptor (CAR) T cell therapy for cancer. In pediatric heart transplant recipients (PHT), the development of PTC may represent increased exposure to don or specific antigens with the potential to induce greater allograft damage through elevated cytokine production; however, the ability of circulating PTC to predict acute cellular rejection (ACR) in PHT is unknown.
We aimed to examine the effectiveness of serial follow-up phone calls as an intervention after clinic visits to enhance compliance with cancer surveillance among heart transplant (HT) patients.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Recent reports indicate risk for fulminant myocarditis in non-transplant patients and severe, potentially fatal rejection in transplant recipients treated with ICIs. As the use of ICIs is expanding, there is an imperative to address gaps in our understanding of risk for ICI use in the post-transplant patient. The aim of this submission is to highlight a case series of thoracic transplant patients treated with ICIs and to introduce a clinical registry of ICI use.
This study was undertaken to identify risk factors using the UNOS database.
There are over 15 million Cancer Survivors (CSr) in the United States and this number is estimated to increase further with improvement in cancer therapeutics and an aging population. In previous studies, CSr undergoing Left Ventricular Assist Device (LVAD) implantation were found to have worse outcomes than patients without a history of cancer. The aim of this study was to ascertain the effect of a previous history of cancer on adverse events and survival in patients undergoing HeartMate 3(HM3) implantation.
We present a series of 104 heart transplants performed for any cancer involving the heart from 1982 to 2017 from the International Society of Heart and Lung Transplant (ISHLT) Thoracic Organ Transplant Registry.